课题基金 / 基金详情

Anthelmintics: From discovery of new drugs to modes of action and resistance

Anthelmintics: From discovery of new drugs to modes of action and resistance
驱虫药:从新药的发现到作用方式和耐药性
批准号:
8646022
负责人:
Adrian J Wolstenholme
金额:
$0.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-01-02 至 2015-01-01

项目摘要

项目成果

Adrian J Wolstenholme的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):R13会议:“驱虫药:实验室研究,从新药的发现到作用模式和对现有药物的抗药性”。 寄生蠕虫包括蛔虫(线虫)、扁虫(吸虫)和绦虫(绦虫),引起许多最普遍的被忽视的热带疾病(NTDS)和许多严重的动物感染。这些线虫包括土壤传播的蠕虫(STH),其中包括蛔虫、钩虫和鞭虫,据估计,这些线虫总共感染了世界上约三分之一的人口,以及丝状线虫,它们会导致淋巴丝虫病和河盲症,这些疾病威胁着近2亿人。吸虫包括感染3亿人的血吸虫和食源性吸虫,吸虫是东南亚国家癌症的主要原因之一。相关动物感染给畜牧业养殖户造成重大生产损失,严重影响犬、马等伴生动物的健康。在所有情况下,预防、治疗和控制这些感染在很大程度上是基于驱虫药,减少和消除一些人类寄生虫的主要努力完全依赖于大规模药物管理计划。淋巴丝虫病的目标是到2020年在全球消除淋巴丝虫病,区域消除血吸虫病和河盲症的计划是在2015年或2020年,具体取决于地区。人们普遍认为,人类和动物都需要新的驱虫药,特别是如果要实现这些雄心勃勃的目标的话。目前用于人类医学的大多数药物最初是为兽医开发的,它们在动物健康中的广泛应用导致了严重的抗药性问题;在人类寄生虫中出现广泛的驱虫抗药性可能会对国际上抗击非传染性疾病的努力造成灾难性的影响。驱虫药发现和使用的历史清楚地表明,医学和兽医寄生虫学家之间需要进行对话,以确保尽可能地消除和控制这些疾病。 我们的会议计划于2014年2月在旧金山梅森堡会议中心举行。旧金山是驱虫药发现的几个领先组织的所在地,之所以被选中,是因为它拥有良好的国内和国际空中联系。 这次会议将对国内和国际与会者开放注册,我们估计将有大约100人参加。如果这次会议促成了新的国际合作,并增加了产业界和学术界研究人员之间的联系和合作,我们将认为会议是成功的。我们打算在会议结束后在开放获取科学期刊上发表5-10篇权威评论文章。
英文摘要
DESCRIPTION (provided by applicant): R13 Conference: 'Anthelmintics: Laboratory Research, from discovery of new drugs to modes of action and resistance to existing ones'. Parasitic helminths, which include roundworms (nematodes), flatworms (trematodes) and tapeworms (cestodes), cause many of the most prevalent Neglected Tropical Diseases (NTDs) and many serious infections of animals. The nematodes include the soil-transmitted helminths (STH), which comprise Ascaris lumbricoides, the hookworms and Trichuris trichiura, which together are estimated to infect about one-third of the world's population, and the filarial nematodes which cause lymphatic filariasis and river blindness, diseases which threaten nearly 200 million people. The trematodes include the schistosomes, which infect 300 million people, and the food-borne trematodes, a group of parasites that are one of the leading causes of cancer in S.E. Asia. Infections of animals with related cause major production losses to livestock farmers and seriously impact the health of companion animals, such as dogs and horses. In all cases, prophylaxis, treatment and control of these infections are based largely on anthelmintic drugs, and the major efforts to reduce and eliminate some of the human parasites are entirely dependent on mass drug administration programs. Lymphatic filariasis has been targeted for global elimination by 2020 and regional elimination of schistosomiasis and river blindness is planned for 2015 or 2020, depending on the region. It is widely accepted that new anthelmintic drugs are required for both human and animal use, especially if these ambitious targets are to be met. Most of the drugs currently used in human medicine were originally developed for veterinary use, and their widespread application in animal health has led to serious problems of drug resistance; the appearance of widespread anthelmintic resistance in human parasites could be disastrous for international efforts to combat NTDs. The history of anthelmintic drug discovery and use clearly shows the need for dialogue between medical and veterinary parasitologists in order to ensure that elimination and control of these diseases proceeds as well as possible. Our conference is planned to take place in San Francisco in February 2014, at the Fort Mason Conference Center. San Francisco is home to several leading groups in anthelmintic drug discovery and was chosen because of its excellent national and international air connections. The meeting will have open registration for national and international attendees, and we estimate that about 100 will attend. We will consider the meeting a success if it results in the formation of new international collaborations and increased links and co-operation between industrial and academic researchers. We intend to produce 5-10 authoritative review articles in an Open Access scientific journal following the meeting.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Trafficking of parasitic nematode ion channels
  • 批准号:
    9165333
  • 项目类别:
  • 资助金额:
    $22.5万
  • 财政年份:
    2016
  • 负责人:
    Adrian J Wolstenholme
  • 依托单位:
Trafficking of parasitic nematode ion channels
  • 批准号:
    9285709
  • 项目类别:
  • 资助金额:
    $18.75万
  • 财政年份:
    2016
  • 负责人:
    Adrian J Wolstenholme
  • 依托单位:
The antifilarial activity of ivermectin and diethylcarbamizine
  • 批准号:
    8756401
  • 项目类别:
  • 资助金额:
    $37.27万
  • 财政年份:
    2014
  • 负责人:
    Adrian J Wolstenholme
  • 依托单位:
The antifilarial activity of ivermectin and diethylcarbamizine
  • 批准号:
    8901920
  • 项目类别:
  • 资助金额:
    $37.5万
  • 财政年份:
    2014
  • 负责人:
    Adrian J Wolstenholme
  • 依托单位:
海外基金